标题
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
作者
关键词
-
出版物
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 4, Pages 697-711
出版商
Rockefeller University Press
发表日期
2012-03-27
DOI
10.1084/jem.20111910
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Abstract 2827: Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
- (2012) Kip A. West et al. CANCER RESEARCH
- STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
- (2012) T. Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- STK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells
- (2011) C. Babij et al. CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Towards systematic functional characterization of cancer genomes
- (2011) Jesse S. Boehm et al. NATURE REVIEWS GENETICS
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
- (2010) Ker Yu et al. CANCER BIOLOGY & THERAPY
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
- (2010) Sachie Marubayashi et al. JOURNAL OF CLINICAL INVESTIGATION
- Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
- (2010) Silvestre Vicent et al. JOURNAL OF CLINICAL INVESTIGATION
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Translating cancer research into targeted therapeutics
- (2010) J. S. de Bono et al. NATURE
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- HSP90 at the hub of protein homeostasis: emerging mechanistic insights
- (2010) Mikko Taipale et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells
- (2010) Y Wang et al. ONCOGENE
- Targeting HSP90 for cancer therapy
- (2009) D Mahalingam et al. BRITISH JOURNAL OF CANCER
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
- (2009) Claudia Scholl et al. CELL
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Purine-Scaffold Hsp90 Inhibitors
- (2009) Tony Taldone et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Update on Hsp90 Inhibitors in Clinical Trial
- (2009) Y. Kim et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- (2009) Martin L. Sos et al. JOURNAL OF CLINICAL INVESTIGATION
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- Perspectives on the development of imatinib and the future of cancer research
- (2009) Brian J Druker NATURE MEDICINE
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- (2009) Leandro C Cerchietti et al. NATURE MEDICINE
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
- (2009) E. Caldas-Lopes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
- (2008) A. Sawai et al. CANCER RESEARCH
- The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
- (2008) M. Barginear et al. CURRENT CANCER DRUG TARGETS
- Targeting Hsp90: small-molecule inhibitors and their clinical development
- (2008) Tony Taldone et al. CURRENT OPINION IN PHARMACOLOGY
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Ras oncogenes: split personalities
- (2008) Antoine E. Karnoub et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started